Within Miscellaneous Manufacturing industry Cryomass Technologies Inc booked the highest Quick Ratio than Cryomass Technologies Inc in the third quarter 2024. While total ranking remained the same in the Q3 2024 compared to the second quarter 2024 at no. .

Explain Quick Ratio?
How much Cash & cash equivalents AFCT�s has?
What are AFCT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AFCT Quick Ratio	(Sep 30 2024) Q3	(Jun 30 2024) Q2	(Mar 31 2024) Q1	(Sep 30 2023) Q3	(Jun 30 2023) Q2
Y / Y Current Liabilities Change	299.37 %	356.25 %	166.85 %	60.3 %	66.53 %
Y / Y Cash & cash equivalent Change	-	-	-98.81 %	-99.7 %	-85.55 %
Quick Ratio MRQ	-	-	0.01	0	0.17
AFCT's Total Ranking	#	#	#	#	#
Seq. Current Liabilities Change	10.92 %	89.91 %	73.68 %	9.16 %	26.72 %
Seq. Cash & cash equivalent Change	-	-	152.21 %	-97 %	-52.37 %

Quick Ratio third quarter 2024 Company Ranking
Within:	No.
Miscellaneous Manufacturing Industry	#
Capital Goods Sector	#
Overall Market	#

Quick Ratio Statistics
High	Average	Low
0	0	0

Financial Statements
Cryomass Technologies Inc's Current Liabilities	$ 7 Millions	Visit AFCT's Balance sheet
Cryomass Technologies Inc's Cash & cash equivalent	$ 0 Millions	Visit AFCT's Balance sheet
Source of AFCT's Sales		Visit AFCT's Sales by Geography

Cumulative Cryomass Technologies Inc's Quick Ratio

AFCT's Quick Ratio for the trailling 12 Months

AFCT Quick Ratio	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months	(Sep 30 2023) 12 Months	(Jun 30 2023) 12 Months
Y / Y Current Liabilities TTM Growth	232.7 %	172.84 %	74.04 %	16.9 %	-41.63 %
Y / Y Cash & cash equivalent TTM Growth	-99.45 %	-95.63 %	-90.72 %	-79.53 %	-48.05 %
Quick Ratio TTM	0	0.03	0.12	0.46	1.06
Total Ranking TTM	# 3672	# 3637	# 2801	# 3554	#
Seq. Current Liabilities TTM Growth	39.45 %	58.86 %	33.01 %	12.91 %	14.36 %
Seq. Cash & cash equivalent TTM Growth	-90.45 %	-65.5 %	-66.28 %	-50.93 %	-23.4 %

Quick ratio ranking by company, industry and sector >> Back to AFCT Financial Strength Comparisons >> Go to Compare AFCT Quick Ratio to its Competitors

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q3 2024 to $7.24 millions, cumulative Quick Ratio decreased to 0 below the Cryomass Technologies Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Miscellaneous Manufacturing industry 35 other companies have achieved higher Quick Ratio than Cryomass Technologies Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2024 from 3637 to 3672.

Explain Quick Ratio?
How much Cash & cash equivalents AFCT�s has?
What are AFCT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Miscellaneous Manufacturing Industry	# 36
Capital Goods Sector	# 257
Within the Market	# 3672

trailing twelve months Quick Ratio Statistics
High	Average	Low
13.13	1.63	0
(Jun 30 2019)		(Jun 30 2017)

Companies with similar Quick Ratio in the quarter ending Sep 30 2024, within Miscellaneous Manufacturing Industry

Quick Ratio

Sep 30 2024 MRQ Cash & cash equivalent

Sep 30 2024 MRQ Current Liabilities

Date modified: 2026-09-18T13:11:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.